ClearPoint Neuro Raises Stock-Sale Ceiling To $150 Million — Its Current Capacity Stays Unchanged
Approximately $27.5 million remains available under the existing prospectus, and the company can choose whether to sell.
ClearPoint Neuro, which develops and sells systems for minimally invasive brain surgery, raised its stock-sale agreement ceiling to $150 million from $50 million on Wednesday, according to its SEC filing. The higher limit includes previous sales and leaves approximately $27.5 million available under its existing prospectus unchanged.
A Higher Ceiling, Same Available Amount
ClearPoint Neuro has already sold approximately $22.5 million of common stock through the original agreement. Those proceeds count toward the amended ceiling; the $150 million limit covers the program's aggregate sales.
Stifel, the company's sales agent, agreed to the higher contractual limit in Wednesday's amendment. The other provisions of the original agreement remain in place.
ClearPoint Neuro established the program on November 7, 2024, using a registration statement—the document covering securities offered to investors—that the SEC declared effective on November 20, 2023. The program lets the company sell common shares into the market from time to time.
ClearPoint Controls Sales And Fees
Stifel will seek buyers under ClearPoint Neuro's instructions. The company can set limits on the price, timing and size of sales, and will pay Stifel a commission of up to 3% of the gross sale price.
ClearPoint Neuro has no obligation to sell additional shares. It can pause offers or end the agreement by giving written notice; Stifel can also terminate it by written notice. The arrangement automatically ends when all shares covered by it have been sold.
Brain Surgery And Pharmaceutical Services
ClearPoint Neuro's main system combines software, hardware and disposable components to help physicians position electrodes for deep brain stimulation, biopsy needles and laser catheters. It also guides drug delivery into the brain.
The company sells a laser therapy system and added a system for managing brain fluid and pressure in intensive care through its 2025 purchase of IRRAS. Its customers include neurosurgeons, other physicians, hospitals and pharmaceutical companies. It provides pharmaceutical customers with preclinical and consulting services as well as products.
To sell beyond the approximately $27.5 million currently available, ClearPoint Neuro will need to file another prospectus supplement.
Sources
- 8-K Filing — ClearPoint Neuro, Inc. (CLPT) — SEC EDGAR
- Exhibit clpt-ex1_1.htm — ClearPoint Neuro, Inc. 8-K exhibit — SEC EDGAR